Eliem Therapeutics, Inc. (ELYM)
$
5.11
-0.05 (-0.98%)
Key metrics
Financial statements
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
What is Eliem Therapeutics, Inc. (ELYM)'s stock forecast?
Analysts predict Eliem Therapeutics, Inc. stock to fluctuate between $2.35 (low) and $11.55 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Eliem Therapeutics, Inc.'s market capitalization?
As of 2024-10-02, Eliem Therapeutics, Inc.'s market cap is $342,677,622, based on 67,060,200 outstanding shares.
How does Eliem Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Eliem Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Eliem Therapeutics, Inc. (ELYM) stock?
To buy Eliem Therapeutics, Inc. (ELYM) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ELYM. Place an order (Market, Limit, etc.).
What is the best time to invest in Eliem Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Eliem Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.30 | Growth: -24.42%.
Where can I find Eliem Therapeutics, Inc.'s investor relations reports?
Visit https://www.eliemtx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Eliem Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Eliem Therapeutics, Inc. stock?
All-time high: $29.69 (2021-08-30) | All-time low: $2.21 (2023-02-17).
What are the key trends affecting Eliem Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb Bio's management team and an external expert who will provide an update to the investment community on the Company's strategy and focus on developing therapeutics for immune-mediated diseases.
globenewswire.com
Name change to "Climb Bio" marks the Company's transition and focus on developing treatments for immune-mediated diseases
globenewswire.com
SEATTLE and CAMBRIDGE, United Kingdom, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.
globenewswire.com
Brett Kaplan, M.D. appointed Chief Operating Officer Nishi Rampal, M.D.
globenewswire.com
Eliem completed the acquisition of Tenet Medicines and concurrent $120 million private placement Eliem to host an Investor Day later in the year to provide an overview of budoprutug (previously referred to as TNT119), pipeline expansion strategy and anticipated milestones Cash and cash equivalents of approximately $220 million expected to fund operations into 2027, to enable the potential attainment of key clinical and development milestones for budoprutug SEATTLE and CAMBRIDGE, United Kingdom, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) (“Eliem” or the “Company”), today reported financial results for the quarter ended June 30, 2024 and provided a business update. “Following the close of the Tenet Medicines acquisition and the concurrent financing, we believe Eliem is well-positioned as we transition to becoming a leading development stage immunology company,” said Dr. Aoife Brennan, CEO of Eliem.
seekingalpha.com
Results from Eliem Therapeutics, Inc.'s phase 1b study, using TNT119 for the treatment of patients with membranous nephropathy, expected by the end of 2024. It is expected that the global membranous nephropathy treatment market could reach $328.4 million by 2034. Two other large market indications that can be targeted using TNT119 are systemic lupus erythematosus and immune thrombocytopenia.
globenewswire.com
SEATTLE and CAMBRIDGE, United Kingdom, June 28, 2024 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), announced today that the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, as part of the annual reconstitution of the Russell stock indexes, effective today.
globenewswire.com
Eliem to focus on advancing TNT119, an anti-CD19 antibody designed to treat a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy
prnewswire.com
PHILADELPHIA , April 15, 2024 /PRNewswire/ -- Kaskela Law LLC, announces that it is investigating Eliem Therapeutics, Inc. (NASDAQ: ELYM) ("Eliem") on behalf of the company's shareholders. The investigation seeks to determine whether Eliem issued false and misleading statements and/or failed to disclose material facts to investors in connection with recent corporate actions, thereby violating the securities laws and causing harm to the company's shareholders.
businesswire.com
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Eliem Therapeutics, Inc. (NASDAQ: ELYM) and Tenet Medicines, Inc. is fair to Eliem shareholders. Halper Sadeh encourages Eliem shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Eliem and its board violated the.
See all news
